Protalix BioTherapeutics, Inc. (PLX) Operating Margin
- Operating margin · 12 months: Value 28.89%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 28.89% | Operating income / revenue. Period ending 2026-06-30. $23.29M ÷ $80.62M × 100 ≈ 28.89% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 23.29M USD | Operating Income (Loss) |
| Revenue | 80.62M USD | |
| Cost of products and services | (m) | |
| Research and development | 19.88M USD | Research and Development Expense |
| Selling, general and administration | 12.62M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23.29M | $80.62M | (m) | $19.88M | $12.62M | 28.89% |
| 2026-03-31 | $19.79M | $76.38M | (m) | $21.52M | $12.13M | 25.91% |
| 2025-12-31 | $-5.50M | $52.74M | (m) | $19.57M | $11.68M | -10.43% |
| 2025-09-30 | $6.37M | $61.84M | (m) | $18.06M | $11.15M | 10.30% |
| 2025-06-30 | $8.23M | $61.95M | (m) | $16.59M | $10.82M | 13.28% |
| 2025-03-31 | $4.63M | $59.76M | (m) | $13.56M | $11.68M | 7.74% |
| 2024-12-31 | $3.92M | $53.40M | (m) | $12.97M | $12.19M | 7.34% |
| 2024-09-30 | $-8.91M | $45.67M | (m) | $11.95M | $13.34M | -19.50% |
| 2024-06-30 | $-14.79M | $38.05M | (m) | $12.62M | $14.41M | -38.85% |
| 2024-03-31 | $8.06M | $59.65M | (m) | $14.13M | $14.96M | 13.52% |
| 2023-12-31 | $10.46M | $65.49M | (m) | $17.09M | $14.96M | 15.97% |
| 2023-09-30 | $13.58M | $63.63M | (m) | $19.61M | $13.91M | 21.34% |
| 2023-06-30 | $12.34M | $67.46M | (m) | $23.32M | $13.09M | 18.29% |
| 2023-03-31 | $-13.60M | $41.14M | (m) | $26.43M | $11.67M | -33.06% |
| 2022-12-31 | $-13.01M | $47.64M | (m) | $29.35M | $11.71M | -27.32% |
| 2022-09-30 | $-16.23M | $47.57M | (m) | $31.37M | $12.08M | -34.11% |
| 2022-06-30 | $-14.98M | $45.44M | (m) | $31.27M | $12.19M | -32.98% |
| 2022-03-31 | $-18.63M | $43.12M | (m) | $31.38M | $12.74M | -43.20% |
| 2021-12-31 | $-20.46M | $38.35M | (m) | $29.73M | $12.73M | -53.36% |
| 2021-09-30 | $-11.92M | $49.30M | (m) | $33.05M | $12.21M | -24.17% |
| 2021-06-30 | $-12.61M | $48.03M | (m) | $33.45M | $12.08M | -26.26% |
| 2021-03-31 | $-5.69M | $52.57M | (m) | $34.95M | $11.10M | -10.82% |
| 2020-12-31 | $2.71M | $62.90M | (m) | $38.17M | $11.15M | 4.31% |
| 2020-09-30 | $2.07M | $61.16M | (m) | $36.89M | $11.21M | 3.39% |
| 2020-06-30 | $3.11M | $64.62M | (m) | $39.20M | $10.98M | 4.81% |
| 2020-03-31 | $-490.00K | $65.90M | (m) | $43.34M | $10.86M | -0.74% |
| 2019-12-31 | $-10.72M | $54.69M | (m) | $44.69M | $9.90M | -19.59% |
| 2019-09-30 | $-16.59M | (m) | (m) | $46.80M | $9.06M | (m) |
| 2019-06-30 | $-18.79M | (m) | (m) | $45.80M | $10.56M | (m) |
| 2019-03-31 | $-19.69M | (m) | (m) | $39.95M | $10.65M | (m) |
| 2018-12-31 | $-19.31M | (m) | (m) | $35.53M | $10.92M | (m) |
| 2018-09-30 | $-42.27M | $9.69M | (m) | $35.35M | $10.64M | -436.17% |
| 2018-06-30 | $-36.07M | $16.55M | (m) | $31.66M | $10.84M | -217.90% |
| 2018-03-31 | $-37.30M | $20.91M | (m) | $33.49M | $11.49M | -178.42% |
| 2017-12-31 | $-36.35M | $19.24M | (m) | $32.17M | $11.53M | -188.93% |
| 2017-09-30 | $-33.66M | $18.85M | (m) | $29.10M | $11.33M | -178.50% |
| 2017-06-30 | $-32.54M | $16.00M | (m) | $28.34M | $10.51M | -203.39% |
| 2017-03-31 | $-31.66M | $11.41M | (m) | $29.05M | $9.90M | -277.54% |
| 2016-12-31 | $-33.16M | $9.20M | (m) | $30.41M | $9.36M | -360.51% |
| 2016-09-30 | $-32.14M | $7.12M | (m) | $31.40M | $7.51M | -451.57% |
| 2016-06-30 | $-30.50M | $3.78M | (m) | $30.11M | $7.66M | -805.95% |
| 2016-03-31 | $-26.15M | $3.35M | (m) | $26.12M | $7.45M | -780.36% |
| 2015-12-31 | $-23.67M | $4.36M | (m) | $24.89M | $7.28M | -542.39% |
| 2015-09-30 | $-19.20M | (m) | (m) | $24.97M | $8.63M | (m) |
| 2015-06-30 | $-22.60M | $12.70M | (m) | $27.77M | $8.39M | -177.93% |
| 2015-03-31 | $-23.58M | $11.35M | (m) | $28.37M | $7.86M | -207.80% |
| 2014-12-31 | $-25.20M | $13.65M | (m) | $29.76M | $9.66M | -184.63% |
| 2014-09-30 | $-28.27M | $13.88M | (m) | $33.13M | (m) | -203.68% |
| 2014-06-30 | $-27.71M | $13.77M | (m) | $32.80M | (m) | -201.25% |
| 2014-03-31 | $-29.16M | $13.61M | (m) | $33.71M | (m) | -214.26% |
| 2013-12-31 | $-27.12M | $10.48M | (m) | $33.31M | (m) | -258.77% |
| 2013-09-30 | $-27.14M | $9.29M | (m) | $32.41M | (m) | -292.15% |
| 2013-06-30 | $-27.05M | $10.73M | (m) | $33.02M | (m) | -252.14% |
| 2013-03-31 | $-10.54M | $34.58M | (m) | $35.57M | (m) | -30.47% |
| 2012-12-31 | $-12.17M | $34.87M | (m) | $36.66M | (m) | -34.91% |
| 2012-09-30 | $-10.86M | $36.06M | (m) | $36.86M | (m) | -30.12% |
| 2012-06-30 | $-14.07M | $33.47M | (m) | $37.88M | (m) | -42.04% |
| 2012-03-31 | $-37.56M | $8.12M | (m) | $36.10M | (m) | -462.59% |
| 2011-12-31 | $-36.53M | $8.39M | (m) | $37.82M | (m) | -435.62% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-29.97M | $6.64M | (m) | $37.69M | (m) | -451.16% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-31.97M | $388.00K | (m) | $27.39M | (m) | -8239.43% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |